· Published by Health Canada · Official notice
This is duplicated text of a letter from Sandoz Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 20, 2013
Dear Health Care Professional,
Subject: Potential for Particulate Matter in Some Vials of Potassium Phosphates Injection USP 10 ml Vials (DIN: 00804789, Product Code: 6750), Potassium Phosphate Monobasic Injection 10 ml Vials (DIN: 00711306, Product Code: 6720) and Sodium Phosphates Injection USP 10 ml Vials (DIN: 00896187, Product Code: 7990)
Sandoz Canada Inc., in consultation with Health Canada, would like to inform you that particulate matter was observed in some vials of one lot of Potassium Phosphates Injection USP 10 ml vials that has not been released on to the Canadian market. Due to the potential for particulate matter in other sterile injectable sodium and potassium phosphate products, healthcare professionals are advised to use an in-line filter when administering any of these phosphate products. These products are distributed in Canada by Baxter. A list of potentially affected products and corresponding lot numbers are attached.
Potassium Phosphates Injection USP is indicated as a potassium supplement, Potassium Phosphate Monobasic Injection as an electrolyte supplement and Sodium Phosphates Injection USP as an electrolyte replenisher. These products are approved for intravenous administration after dilution.
Inadvertent injection of particulate matter could result in local inflammation, phlebitis, allergic response and/or embolization in the body. Since the release of the potentially affected phosphate injectable products, no adverse event reports related to this issue were received at Sandoz Canada Inc.
As a precautionary measure, all parenteral drug products should be inspected visually for the presence of particulate matter. Every container whose contents show evidence of visible particulates should not be used and should be reported to Sandoz Canada.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious adverse reaction or other serious or unexpected adverse reactions in patients receiving Potassium Phosphates Injection USP, Potassium Phosphate Monobasic Injection or Sodium Phosphates Injection USP should be reported to Sandoz Canada Inc. or Health Canada.
Sandoz Canada Inc.
145 Jules Léger
Bouchervillle, Quebec, Canada
J4B 7K8
Tel: 1-800-343-8839 ext. 4636
Fax: 1-888-243-6221
To correct your mailing address or fax number, contact Sandoz Canada Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
If you have questions regarding the above information, please contact our Drug Information Department at 1-800-343-8839 (4636). If you have questions regarding products availability, please call Baxter Customer Service at 1-888-719-9955.
Sincerely,
original signed by
Michèle Théberge
Vice-President, Quality Unit
Len Arsenault
Vice-President, Scientific Affairs
References:
| Baxter Product Code | Product Description | Lot number | Expiry date |
|---|---|---|---|
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | BG4591 | 31/12/2013 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | BH9050 | 31/01/2014 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | BL1261 | 28/02/2014 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | BS1390 | 31/05/2014 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | BW8396 | 31/08/2014 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CB6612 | 30/11/2013 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | CB2566 | 30/11/2014 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CF3227 | 31/01/2014 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CC4793 | 31/12/2013 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CM2759 | 31/05/2015 |
| 6750 | POSTASIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CC4869 | 31/12/2014 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | CD1657 | 31/12/2014 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | CF2454 | 31/01/2015 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | CH1609 | 31/03/2015 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CU9275 | 30/09/2015 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CV0423 | 30/09/2015 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CZ1458 | 30/11/2015 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DC0197 | 31/01/2016 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DA1733 | 31/12/2015 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | CZ4425 | 30/11/2015 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DB8315 | 31/01/2016 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DC1368 | 31/01/2016 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | DF5688 | 31/03/2016 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DG1641 | 31/03/2016 |
| 6720 | POTASSIUM PHO MONOBASIC 10ML 10LIVI CA | DG2451 | 31/03/2016 |
| 6750 | POTASSIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DC0197 | 31/01/2016 |
| 7990 | SODIUM PO4 3MMOLP/ML 10ML 10LIVI CA | DG5193 | 31/03/2016 |